CRESCENT BIOPHARMA, INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- CRESCENT BIOPHARMA, INC. stock issued during period, value, new issues for the quarter ending 2024-12-31 was $1.31M.
- CRESCENT BIOPHARMA, INC. stock issued during period, value, new issues for the quarter ending 2023-03-31 was $28.71M.
- CRESCENT BIOPHARMA, INC. stock issued during period, value, new issues for the quarter ending 2021-03-31 was $9.56M.
- CRESCENT BIOPHARMA, INC. stock issued during period, value, new issues for the quarter ending 2020-12-31 was $3.71M.
- CRESCENT BIOPHARMA, INC. stock issued during period, value, new issues for fiscal 2025 was $185.00M.
- CRESCENT BIOPHARMA, INC. stock issued during period, value, new issues for fiscal 2023 was $28.71M, a 590.50% increase from fiscal 2022.
- CRESCENT BIOPHARMA, INC. stock issued during period, value, new issues for fiscal 2022 was $4.16M, a 61.14% decline from fiscal 2021.
- CRESCENT BIOPHARMA, INC. stock issued during period, value, new issues for fiscal 2021 was $10.70M, a 39.97% decline from fiscal 2020.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2025-12-31 | $185.00M 10-K · filed 2026-02-26 | |
| 2024-12-31 | $1.31M 10-K · filed 2026-02-26 | |
| 2023-12-31 | $28.71M 10-K · filed 2025-02-13 | |
| 2023-03-31 | $28.71M 10-Q · filed 2024-11-13 | |
| 2022-12-31 | $4.16M 10-K · filed 2024-03-27 | |
| 2021-12-31 | $10.70M 10-K · filed 2024-03-27 | |
| 2021-03-31 | $9.56M 10-Q · filed 2022-11-09 | $27.38M derived: sum of 4 quarters · filed 2023-03-29 |
| 2020-12-31 | $3.71M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $17.82M 10-K · filed 2023-03-29 |
| 2020-09-30 | $4.55M 10-Q · filed 2021-11-02 | |
| 2020-06-30 | $9.57M 10-Q · filed 2021-11-02 | |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-02 | $128.43M 10-K · filed 2021-03-02 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | |
| 2018-06-30 | -$10.92K 10-Q · filed 2019-08-01 | |
| 2018-03-31 | $128.44M 10-Q · filed 2019-05-02 | |
| 2017-12-31 | $113.55M 10-K · filed 2020-02-28 | |
| 2016-12-31 | $23.60M 10-K · filed 2019-03-06 | |
| 2014-12-31 | $57.25M 10-K · filed 2017-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |